LPCN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.12%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Lipocine Insider Trading History Chart

Lipocine Share Price & Price History

^$5.00

▲ +0.29 (6.16%)

As of 11/21/2024 01:00 AM ET

Days: 30 | 90 | 365

The AI Crash Begins November 30th

From Brownstone Research | Ad

You can click here to view it now (for free)

Lipocine Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/25/2023	Mahesh V. Patel	CEO	Buy	8,706	$5.03	$43,791.18	107,418
3/24/2023	Mahesh V. Patel	CEO	Buy	8,823	$5.44	$47,997.12	98,711
3/20/2023	Richard Dana Ono	Director	Buy	235	$5.78	$1,358.30	830
3/17/2023	Mahesh V. Patel	CEO	Buy	2,941	$5.61	$16,499.01	89,887
11/22/2022	Spyros Papapetropoulos	Director	Buy	1,278	$7.99	$10,211.22	1,278
9/27/2022	Mahesh V. Patel	CEO	Buy	5,882	$6.97	$40,997.54	82,534
5/17/2022	Krista Fogarty	Insider	Buy	735	$14.62	$10,745.70	735
5/16/2022	Mahesh V. Patel	CEO	Buy	2,941	$13.09	$38,497.69	76,652

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

SEC Filings (Institutional Ownership Changes) for Lipocine (NASDAQ:LPCN)

9.11% of Lipocine stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Lipocine Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/9/2024	Renaissance Technologies LLC	25,697	$0.21M	0.0%	+21.8%	0.480%
8/9/2024	Dimensional Fund Advisors LP	11,870	$98K	0.0%	N/A	0.222%
1/29/2024	Wealth Effects LLC	14,639	$41K	0.0%	-22.0%	0.275%
10/16/2023	Wealth Effects LLC	18,761	$56K	0.0%	-35.9%	0.353%
7/18/2023	Wealth Effects LLC	29,273	$0.15M	0.1%	-96.1%	0.563%
6/5/2023	EP Wealth Advisors LLC	66,983	$13.40M	0.2%	N/A	1.288%
5/4/2023	Wealth Effects LLC	756,674	$0.24M	0.1%	-35.8%	0.855%
2/13/2023	Wealthspan Partners LLC	73,950	$29K	0.0%	N/A	0.084%
2/2/2023	Wealth Effects LLC	1,178,834	$0.47M	0.3%	-3.0%	1.332%
2/2/2023	Bailard Inc.	82,957	$32K	0.0%	N/A	0.094%
11/7/2022	Virtu Financial LLC	93,411	$42K	0.0%	N/A	0.106%
8/3/2022	Carson Advisory Inc.	52,000	$42K	0.0%	N/A	0.059%
7/27/2022	Bailard Inc.	74,400	$60K	0.0%	N/A	0.084%
7/22/2022	Aaron Wealth Advisors LLC	145,045	$0.12M	0.0%	+23.4%	0.164%
5/13/2022	EAM Investors LLC	657,804	$0.90M	0.2%	N/A	0.743%
5/10/2022	Aaron Wealth Advisors LLC	117,552	$85.81M	1.2%	N/A	0.133%
4/26/2022	Kestra Advisory Services LLC	307,300	$0.42M	0.0%	+27.9%	0.347%
2/14/2022	GSA Capital Partners LLP	440,432	$0.44M	0.1%	+39.7%	0.499%
2/9/2022	Wealth Effects LLC	1,489,434	$1.48M	0.6%	N/A	1.687%
11/15/2021	GSA Capital Partners LLP	315,308	$0.34M	0.0%	+122.8%	0.357%
11/10/2021	Mercer Global Advisors Inc. ADV	313,111	$0.34M	0.0%	+6.8%	0.355%
11/9/2021	Barclays PLC	24,075	$26K	0.0%	+243.3%	0.027%
10/19/2021	Kestra Advisory Services LLC	249,418	$0.27M	0.0%	+256.3%	0.282%
8/16/2021	State Street Corp	304,617	$0.43M	0.0%	+2,356.6%	0.345%
8/13/2021	Northern Trust Corp	173,117	$0.24M	0.0%	+16.8%	0.196%
8/13/2021	LPL Financial LLC	62,750	$88K	0.0%	+46.8%	0.071%
8/13/2021	Geode Capital Management LLC	760,586	$1.06M	0.0%	+26.0%	0.861%
8/13/2021	Vanguard Group Inc.	3,815,348	$5.34M	0.0%	+6.4%	4.321%
8/12/2021	XTX Topco Ltd	20,706	$29K	0.0%	-30.8%	0.023%
8/11/2021	Bank of New York Mellon Corp	110,204	$0.15M	0.0%	+99.6%	0.125%
8/11/2021	BlackRock Inc.	1,582,415	$2.22M	0.0%	-2.5%	1.792%
8/10/2021	Mercer Global Advisors Inc. ADV	293,111	$0.41M	0.0%	+38.8%	0.332%
8/10/2021	Principal Financial Group Inc.	20,382	$29K	0.0%	N/A	0.023%
8/5/2021	GSA Capital Partners LLP	141,521	$0.20M	0.0%	+12.3%	0.160%
5/19/2021	Virtu Financial LLC	191,387	$0.29M	0.0%	-8.0%	0.217%
5/19/2021	Squarepoint Ops LLC	84,001	$0.13M	0.0%	+515.5%	0.095%
5/18/2021	Cubist Systematic Strategies LLC	55,200	$83K	0.0%	N/A	0.063%
5/18/2021	Jane Street Group LLC	29,060	$44K	0.0%	N/A	0.033%
5/17/2021	Price T Rowe Associates Inc. MD	89,264	$0.14M	0.0%	N/A	0.101%
5/17/2021	Ameriprise Financial Inc.	702,000	$1.06M	0.0%	-4.2%	0.795%
5/14/2021	MML Investors Services LLC	41,000	$62K	0.0%	N/A	0.046%
5/14/2021	XTX Topco Ltd	29,929	$45K	0.0%	N/A	0.034%
5/13/2021	Barclays PLC	21,594	$33K	0.0%	N/A	0.024%
5/12/2021	Northern Trust Corp	148,222	$0.22M	0.0%	+19.3%	0.168%
5/12/2021	Geode Capital Management LLC	603,713	$0.91M	0.0%	+33.9%	0.684%
5/11/2021	Mercer Global Advisors Inc. ADV	211,210	$0.32M	0.0%	-27.5%	0.239%
5/10/2021	GSA Capital Partners LLP	125,993	$0.19M	0.0%	-32.3%	0.143%
2/24/2021	Virtu Financial LLC	207,996	$0.28M	0.0%	N/A	0.253%
2/12/2021	Mercer Global Advisors Inc. ADV	291,210	$0.40M	0.0%	+20.7%	0.355%
2/11/2021	Northern Trust Corp	124,210	$0.17M	0.0%	+40.4%	0.151%
2/9/2021	Bank of New York Mellon Corp	60,886	$83K	0.0%	N/A	0.074%
2/5/2021	BlackRock Inc.	1,618,913	$2.20M	0.0%	+0.5%	1.972%
2/4/2021	GSA Capital Partners LLP	185,992	$0.25M	0.0%	+133.0%	0.227%
1/20/2021	Kestra Advisory Services LLC	346,118	$0.45M	0.0%	N/A	0.527%
12/10/2020	Mercer Global Advisors Inc. ADV	241,210	$0.34M	0.0%	-11.3%	0.367%
11/6/2020	BlackRock Inc.	1,610,701	$2.27M	0.0%	+122.7%	2.452%
11/6/2020	GSA Capital Partners LLP	79,817	$0.11M	0.0%	+32.2%	0.122%

Data available starting January 2016

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $5.00

$4.71

$5.15

50 Day Range

MA: $5.07

$4.08

$6.09

52 Week Range

Now: $5.00

$2.38

$11.79

Volume

13,627 shs

Average Volume

46,050 shs

Market Capitalization

$26.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Who are the company insiders with the largest holdings of Lipocine?: Lipocine's top insider shareholders include:
Mahesh V Patel (CEO)
Spyros Papapetropoulos (Director)
Richard Dana Ono (Director)
Learn More about top insider investors at Lipocine.